CDMC 2018: Shifting gears in the management of diabetes and CVD

Meeting report of the Cardio Diabetes Master Class (CDMC) held in november 2018 in Dubai, UAE as an educational service for participants with video and slides. The Cardio Diabetes Master Class is an initiative of PACE-CME

Recent

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Slides: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?

Slides (presentation) - Nov. 27, 2018 - Dubai UAE - Dr Adie Viljoen Stevenage, United Kingdom - Cardio Diabetes Master Class 2018

Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i

Lecture - Nov. 16, 2018 - Dubai, UAE - Prof. Eduard Montanya Barcelona, Spain

Lecture: Shifting gears in CVD & T2DM: What is the rationale for new diabetes interventions in the course of CVD?

Lecture - Nov. 16, 2018 - Dubai, UAE - Prof John E Deanfield, London, United Kingdom

Lecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?

Lecture - Nov. 16, 2018 - Dubai, UAE - Dr Adie Viljoen Stevenage, United Kingdom

Lecture: Targeting CV risk: Implications for clinical management of patients with T2DM & CVD

Lecture - Nov. 16, 2018 - Dubai, UAE - Prof Richard Hobbs, Oxford, United Kingdom

Lecture: The GLP1 landscape - refining our understanding

Lecture - Nov. 17, 2018 - Dubai, UAE - Dr Adie Viljoen, Stevenage, United Kingdom

Lecture: Screening for Diabetes: When is it meaningful and how should it be performed

Lecture - Nov. 17, 2018 - Dubai, UAE - Prof. Lars Ryden, Stockholm, Sweden

Lecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions

Lecture - Nov. 17, 2018 - Dubai, UAE - Prof. Richard Hobbs, Oxford

Lecture: Diabetes: The new challenge in cardiovascular risk management

Lecture - Nov. 16, 2018 - Dubai, UAE - Prof Lars Ryden, Stockholm, Sweden

Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice

Lecture - Nov. 16, 2018 - Dubai UAE - Prof John E Deanfield

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Two choices of drugs that reduce CV risk in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits.

Cardio Diabetes Masterclass Dubai Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits .

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Prof. Montanya DMdiscusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trials, respectively.

Cardio Diabetes Masterclass Dubai Prof. Montanya discusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trial, respectively.

Slides: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?